Amer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 1, 2023

In this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of acute myeloid leukemia (AML) classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.

Catch up on earlier episodes of The HemOnc Pulse here.

Advertisement
Advertisement
Advertisement
Editorial Board